What's Happening?
Eli Lilly and Company is promoting proactive brain health through scientific advancements aimed at early detection and care for Alzheimer's disease. With over 7 million adults in the U.S. affected by Alzheimer's,
the disease is projected to double by 2050. Despite Medicare coverage, less than one in five seniors undergo standardized cognitive assessments. Eli Lilly's Brain Health Matters campaign, featuring actress Julianne Moore, seeks to normalize cognitive assessments and raise awareness about early detection. Recent research suggests lifestyle changes can improve cognitive outcomes, and new FDA-cleared blood biomarker tests offer less invasive diagnostic options.
Why It's Important?
The growing prevalence of Alzheimer's disease poses significant challenges for healthcare systems and families. Early detection and proactive care can improve outcomes and reduce the burden on caregivers. Eli Lilly's initiatives highlight the importance of integrating brain health into wellness conversations, potentially leading to earlier diagnoses and better management of the disease. The advancements in diagnostic tools, such as blood biomarker tests, represent a shift towards more accessible and less invasive methods, which could improve healthcare equity and patient outcomes.
